*All Times Shown in PST

7:30 am Morning “Coffee Room” Networking

8:00 am Roundtable Discussion: Biomarkers in Immuno-oncology – from Preclinical Approaches through Clinical Trials


  • Hosted by Covance

8:55 am Chair’s Opening Remarks

Establishing Success in Preclinical Development of Cell Therapy Products for I/O Applications

9:00 am In Vivo Screens in Mouse Tumor Models Treated with Pools of Edited CAR-T Cells to Identify the Next Generation of iPSC Derived Immunotherapies for Cancer

  • Eric Sung Associate Scientist – In Vivo Pharmacology, Fate Therapeutics


  • Introduction to Fate’s iPSC Derived Immunotherapy Platform
  • Novel multiplexed approach to generate pools of engineered CAR-T clones with different edits for combinatorial testing in vitro and in vivo
  • Using genomics to screen pools of edited CAR-T in mouse tumor models to identify winning clones with specific edits

9:20 am Humanized Models Enabling Enhanced Clinical Relevancy & Translatability

  • Kader Thiam Senior Vice President Discovery - Preclinical Models & Services, GenOway


  • Immune checkpoint humanized mouse models
    • Assessment of biologics efficacy & combo-therapy
    • Importance of model design on overall model performances
  • BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments
    • Analysis of the human immune system & effector function

9:50 am A Patient-Derived Glioblastoma Organoid Model for Testing Personized Treatment Strategies

  • Hongjun Song Professor - Neuroscience, University of Pennsylvania


  • A simple patient-derived glioblastoma organoid model and biobank that recapitulates inter- and intra-tumoral heterogeneity
  • Testing personized drug treatment of strategy based on mutation and gene expression characteristics of the tumor
  • Application of the glioblastoma organoid model for CAR-T treatment testing

10:10 am Using Humanized Models to Improve Translational Success for In Vivo Efficacy Studies of Tumors


  • Introduction of target-humanized mouse models including IO target, cytokine and cytokine receptor humanized mouse models for antibodies, bispecific and combination therapies used in immuno-oncology
  • Discussion of using B-NDG and second generation B-NDG based immune system reconstitution mouse models as tumor models in different therapeutic modalities including antibody and cell therapy

10:40 am Discussion/Q&A

  • Goutham Narla Professor - Medicine, University of Michigan
  • Eric Sung Associate Scientist – In Vivo Pharmacology, Fate Therapeutics
  • Kader Thiam Senior Vice President Discovery - Preclinical Models & Services, GenOway
  • Hongjun Song Professor - Neuroscience, University of Pennsylvania
  • Mari Kuraguchi Director - In Vivo Pharmacology, Biocytogen

11:00 am Virtual Networking

11:30 am Morning Refreshments

Enhancing Clinical Translatability of Immune Oncology Cell-Based Strategies

11:40 am SCC VII as a Novel Syngeneic Tumor Model to Assess Immune Checkpoint Blockade Resistance and CD4+ T Cell Help for CD8+ Cytotoxic T Lymphocytes


  • Strategies for neoantigen identification rely on potential epitopes for only CD8+ T cells based on prediction algorithms despite functional cooperation between these cells and the CD4+ T cell subset is necessary for optimal cell-mediated immunity
  • Using SCC VII as a poorly-immunogenic tumor model, which resembles human head and neck squamous cell carcinoma (HNSCC) in several key features, we have applied a novel functional approach to identify the subset of expressed mutations targeted as neoantigens by natural CD4+
    and CD8+ T cell responses
  • A single mutation recognized by both subsets is capable of eradicating established, immune checkpoint blockade resistant tumors in the setting of therapeutic vaccination provided the relevant epitopes are physically linked

12:00 pm MPA/DMBA-Driven Mammary Carcinomas as a Model of Luminal B Breast Cancer

  • Lorenzo Galluzzi Assistant Professor – Cell Biology & Radiation Oncology, Weill Cornell Medicine


  • Hormone receptor (HR)+ breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in
    patients with HR+ BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts
  • We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2- BC, including limited immune infiltration poor sensitivity to ICBs
  • Moreover, M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance

12:20 pm Preclinical Evaluation of NKX019, a CD19-targeting CAR NK Cell


  • NKX019 is a highly potent CD19-directed CAR NK cell therapy with specific cytotoxic activity against CD19+ B-ALL tumors
  • NKX019 displays enhanced in vitro expansion and longer in vivo half-life than non-engineered NK cells
  • NKX019 exhibits advantages compared to CAR19+ T cells including faster cytotoxic kinetics and limited production of cytokines associated with CRS

12:40 pm Discussion/Q&A

1:00 pm Roundtable: No One Size Fits All Approach – Choosing the Right Preclinical Model for the Right I/O Question

  • Shon Green Senior Director - Translational Sciences, Umoja Biopharma

Expanding the Complexity of Pre-Clinical Modelling through Next Generation Platforms

1:50 pm MADR: Multiplex In Vivo and In Vitro Genetically Engineered Tumor Models for Immuno-Oncology Preclinical Discovery & Testing

  • Joshua Breunig Associate Professor, Cedars-Sinai Medical Center & UCLA


  • Using mosaic analysis with dual recombinase-mediated cassette exchange (MADR) to generate “personalized” tumor subtypes
  • Diversifying the use of MADR for the generation of autochthonous in vivo modelling, syngeneic modelling, and multiplex organoid modelling of tumors
  • Employing MADR as preclinical platforms for immuno-oncology testing and discovery

2:10 pm Bioengineered Tumor Organoids for Personalized Medicine Applications

  • Shay Soker Professor, Wake Forest School of Medicine


  •  Immunotherapy have been welcomed as a significant advance in the management of multiple types of cancer, however some patients may be innately unresponsive or acquire resistance over the course of treatment
  • Reconstructing the patient’s own tumor in vitro, in the form of tumor organoids containing tumor cells along with associated stroma
  • Patient-specific tumor organoids have the potential not only to support personalized medicine decisions but also uncover mechanism of therapy resistance

2:30 pm Discussion/Q&A

2:50 pm Chair’s Closing Remarks & End of 5th PREDiCT: Tumor Models for Immuno-Oncology 2021